[{"id":"b9a406bd-d975-4b31-a433-86da8522fc92","acronym":"TAS-120-202","url":"https://clinicaltrials.gov/study/NCT04189445","created_at":"2021-01-19T19:00:59.221Z","updated_at":"2025-02-25T16:44:46.191Z","phase":"Phase 2","brief_title":"Futibatinib in Patients With Specific FGFR Aberrations","source_id_and_acronym":"NCT04189445 - TAS-120-202","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 11/11/2024","primary_completion_date":" 11/11/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-05"},{"id":"9d94409b-3124-4594-8d29-7cfddaf92a43","acronym":"FOENIX-CCA4","url":"https://clinicaltrials.gov/study/NCT05727176","created_at":"2023-02-14T18:02:28.005Z","updated_at":"2025-02-25T17:02:23.376Z","phase":"Phase 2","brief_title":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","source_id_and_acronym":"NCT05727176 - FOENIX-CCA4","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-03"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"c8879055-5cfc-4980-bb0d-ebf82077c424","acronym":"FOENIX-MBC2 TAS-120-201","url":"https://clinicaltrials.gov/study/NCT04024436","created_at":"2021-01-18T19:45:26.836Z","updated_at":"2024-07-02T16:35:00.592Z","phase":"Phase 2","brief_title":"A Study of TAS-120 in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT04024436 - FOENIX-MBC2 TAS-120-201","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • PD-L1 • FGFR2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification","tags":["HER-2 • PD-L1 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 08/30/2019","start_date":" 08/30/2019","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2024-05-29"},{"id":"47f92e4c-0373-4b92-b1aa-e6cda3cd31e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04828486","created_at":"2021-04-02T11:53:33.440Z","updated_at":"2024-07-02T16:35:12.332Z","phase":"Phase 2","brief_title":"Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer","source_id_and_acronym":"NCT04828486","lead_sponsor":"Mayo Clinic","biomarkers":" FGF19","pipe":" | ","alterations":" FGF19 positive","tags":["FGF19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGF19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lytgobi (futibatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/07/2021","start_date":" 05/07/2021","primary_txt":" Primary completion: 05/06/2025","primary_completion_date":" 05/06/2025","study_txt":" Completion: 05/06/2025","study_completion_date":" 05/06/2025","last_update_posted":"2024-03-29"},{"id":"b2993259-256a-4604-9f68-777de564f0ad","acronym":"FOENIX-CCA2","url":"https://clinicaltrials.gov/study/NCT02052778","created_at":"2021-01-17T17:33:24.806Z","updated_at":"2024-07-02T16:35:13.841Z","phase":"Phase 1/2","brief_title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02052778 - FOENIX-CCA2","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Completed","enrollment":" Enrollment 407","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 05/29/2021","study_completion_date":" 05/29/2021","last_update_posted":"2024-03-20"},{"id":"ac368dac-d72f-4556-a324-0ba3a854aa2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05945823","created_at":"2023-07-14T18:08:59.015Z","updated_at":"2024-07-02T16:35:17.589Z","phase":"Phase 2","brief_title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","source_id_and_acronym":"NCT05945823","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • oxaliplatin • Lytgobi (futibatinib) • irinotecan • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 07/13/2023","start_date":" 07/13/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-26"},{"id":"7081cc15-ba4e-458b-8ca4-38802c059b4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04507503","created_at":"2021-01-19T20:11:47.503Z","updated_at":"2024-07-02T16:35:17.897Z","phase":"","brief_title":"Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements","source_id_and_acronym":"NCT04507503","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-23"},{"id":"cee8aba7-65f5-4dfb-8178-d79ff5369a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04999761","created_at":"2021-08-11T15:53:36.773Z","updated_at":"2024-07-02T16:35:19.007Z","phase":"Phase 1","brief_title":"AB122 Platform Study","source_id_and_acronym":"NCT04999761","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 715","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-02-16"}]